Get the Stockscreener App
18.19
1.52%
-0.28
After Hours:
18.11
-0.08
-0.44%
Moonlake Immunotherapeutics stock is traded at $18.19, with a volume of 653.59K.
It is down -1.52% in the last 24 hours and up +5.63% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
See More
Previous Close:
$18.47
Open:
$18.5
24h Volume:
653.59K
Relative Volume:
0.61
Market Cap:
$1.34B
Revenue:
-
Net Income/Loss:
$-230.32M
P/E Ratio:
-5.159
EPS:
-3.5259
Net Cash Flow:
$-196.04M
1W Performance:
+3.65%
1M Performance:
+5.63%
6M Performance:
+43.57%
1Y Performance:
-52.77%
1-Day Range:
$18.00
$18.75
1-Week Range:
$15.76
$18.75
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
18.19 | 1.36B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Upgrade | Wolfe Research | Underperform → Outperform |
| Mar-19-26 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Jan-15-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-09-26 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
Should FDA Alignment on Sonelokimab’s HS Label Strategy Require Action From MoonLake Immunotherapeutics (MLTX) Investors? - simplywall.st
MLTX stock soars overnight after FDA backs skin drug filing — analyst sees over 300% upside on 'best-in-class' label - MSN
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors? - Kavout
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - MSN
MoonLake’s lead asset shows durability in late-stage HS studies - MSN
MoonLake (MLTX) shares gain after positive FDA meeting on sonelokimab filing - MSN
MoonLake clears a key regulatory hurdle, and shares rocket - MSN
MLTX Technical Analysis | Trend, Signals & Chart Patterns | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
MoonLake ImmunotherapeuticsClass A Ordinary Shares (NQ: MLTX - The Chronicle-Journal
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive FDA Pre BLA Outcome For Sonelokimab - simplywall.st
FDA aligns with MoonLake on lead drug submission plans, stock soars - MSN
Cormorant Asset Management and Bihua Chen report 6.25% stake in MoonLake (MLTX) - Stock Titan
(MLTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
MLTX Stock Chart | MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ:MLTX) - ChartMill
Insider Sell Alert: Matthias Bodenstedt Sells Shares of MoonLake Immunotherapeutics (MLTX) - GuruFocus
MoonLake Immunotherapeutics (MLTX) CFO logs pre-planned sale of 13,653 shares - Stock Titan
Equities Analysts Set Expectations for MLTX Q1 Earnings - MarketBeat
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $45 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Is Up 7.3% After FDA Aligns on Sonelokimab BLA Pathway - Yahoo Finance
Needham raises Moonlake stock price target to $30 on BLA filing plans - Investing.com
Needham raises Moonlake stock price target to $30 on BLA filing plans By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics: Buy Rating Reiterated on De-Risked Path to 2026 BLA and Robust SLK Data; $30 Price Target Maintained - TipRanks
Update: MoonLake Immunotherapeutics Q1 Net Loss Widens - Moomoo
MoonLake Gains FDA Clearance for Sonelokimab Hidradenitis Suppurativa Label - The Clinical Trial Vanguard
MoonLake price target raised to $45 from $40 at H.C. Wainwright - TipRanks
Down-But-Not-Out Biotech Rockets On A Key FDA Decision - Investor's Business Daily
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $12 to $70 - 富途牛牛
Phil Nadeau Reiterates Buy on MoonLake Immunotherapeutics as Sonelokimab Advances Toward 2027 Launch with $3B+ Peak Sales Potential - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Posts Earnings Results, Misses Estimates By $0.07 EPS - MarketBeat
H.C. Wainwright raises Moonlake stock price target on FDA progress - Investing.com UK
FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars - Benzinga
MoonLake Immunotherapeutics Announces Positive FDA Pre-BLA Meeting and Reports Q1 2026 Financial Results - Minichart
H.C. Wainwright raises Moonlake stock price target on FDA progress By Investing.com - Investing.com Australia
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bodenstedt Matthias | Chief Financial Officer |
Apr 14 '26 |
Sale |
19.56 |
2,426 |
47,453 |
1,186,084 |
| Santos da Silva Jorge | Chief Executive Officer |
Apr 10 '26 |
Sale |
18.41 |
98,127 |
1,806,518 |
2,976,766 |
| Santos da Silva Jorge | Chief Executive Officer |
Apr 13 '26 |
Sale |
18.23 |
51,873 |
945,645 |
2,924,893 |
| Bodenstedt Matthias | Chief Financial Officer |
Apr 09 '26 |
Sale |
18.94 |
85,870 |
1,626,378 |
1,190,435 |
| Bodenstedt Matthias | Chief Financial Officer |
Apr 10 '26 |
Sale |
19.51 |
1,925 |
37,557 |
1,188,510 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):